Double strike on TRKC: The nobiletin-SAHA alliance
Peer-Reviewed Publication
Updates every hour. Last Updated: 29-Oct-2026 00:16 ET (29-Oct-2026 04:16 GMT/UTC)
A new mechanism based on a novel natural BH3 mimetic nobiletin combined with an HDAC inhibitor to synergistically regulate apoptosis and autophagy in non-small cell lung cancer (NSCLC) by down-regulating TRKC expression is provided, and a new strategy for NSCLC therapy is opened.
Salk Institute researchers investigated the impacts of entinostat, a drug that targets HDAC proteins, and found it inactivates DNA damage repair genes in pancreatic cancer cells. Their discovery led to new treatment strategies that pair entinostat with DNA-damaging therapies, as well as the development of a nanoparticle-based delivery approach that limits toxicity by selectively delivering entinostat to tumors. The findings could improve treatment outcomes and expand therapeutic options for pancreatic cancer, and similar strategies could be applied for treating other cancer types that resist DNA-damaging therapies.
A new study led by researchers at WashU Medicine suggests that younger generations are aging biologically faster than their older counterparts. This faster biological aging was also linked to early-onset cancers.
The award, which comes with $100,000, the highest funding level awarded through the OutSmarting Osteosarcoma program, will support Nowicki’s research into the development of a next-generation CAR-T cell therapy for osteosarcoma, the most common bone cancer in children and adolescents.
Researchers at the Icahn School of Medicine at Mount Sinai have found that wearable devices may help clinicians detect cytokine release syndrome (CRS)—a common and potentially serious side effect of CAR-T cell therapy—hours earlier than standard hospital monitoring in patients with multiple myeloma, a blood cancer that begins in plasma cells in the bone marrow.